Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 7 points (0.0%) at 17,094 as of Thursday, July 24, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,609 issues advancing vs. 1,334 declining with 169 unchanged. The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the sector include Varian Medical Systems ( VAR), down 6.1%, Jazz Pharmaceuticals ( JAZZ), down 2.1%, Novo Nordisk A/S ( NVO), down 1.5%, Stryker Corporation ( SYK), down 1.2% and Shire ( SHPG), down 0.8%. Top gainers within the sector include Intuitive Surgical ( ISRG), up 2.5%, Thermo Fisher Scientific ( TMO), up 1.1% and Express Scripts ( ESRX), up 0.7%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Regeneron Pharmaceuticals is down $4.76 (-1.5%) to $305.51 on light volume. Thus far, 249,500 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 853,200 shares. The stock has ranged in price between $304.66-$311.50 after having opened the day at $310.40 as compared to the previous trading day's close of $310.27. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $30.3 billion and is part of the drugs industry. Shares are up 12.7% year-to-date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow. Get the full Regeneron Pharmaceuticals Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.